Edesa Biotech, Inc. financial data

Symbol
EDSA on Nasdaq
Location
Markham
Fiscal year end
30 September
Latest financial report
10-Q - Q4 2025 - 13 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1501% % 1022%
Debt-to-equity 55% % 192%
Return On Equity -56% % 74%
Return On Assets -53% % 58%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8,333,823 shares 140%
Common Stock, Shares, Outstanding 8,333,823 shares 140%
Entity Public Float $13,978,238 USD 26%
Common Stock, Value, Issued $57,899,593 USD 22%
Weighted Average Number of Shares Outstanding, Basic 7,972,532 shares 138%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $3,773,647 USD 18%
General and Administrative Expense $4,580,613 USD 19%
Operating Income (Loss) $8,354,260 USD -18%
Nonoperating Income (Expense) $539,121 USD -43%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $1,749,464 USD -4.9%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $7,815,939 USD -28%
Earnings Per Share, Basic -1.07 USD/shares 43%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $12,100,000 USD 656%
Assets, Current $12,717,487 USD 514%
Property, Plant and Equipment, Net $0 USD -100%
Operating Lease, Right-of-Use Asset $0 USD -100%
Assets $14,710,442 USD 253%
Liabilities, Current $756,163 USD -60%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $1,832,827 USD -0.48%
Accumulated Other Comprehensive Income (Loss), Net of Tax $171,086 USD 24%
Retained Earnings (Accumulated Deficit) $68,196,040 USD -13%
Stockholders' Equity Attributable to Parent $13,954,279 USD 516%
Liabilities and Equity $14,710,442 USD 253%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,087,334 USD -38%
Net Cash Provided by (Used in) Financing Activities $3,355,419 USD 62%
Common Stock, Shares, Issued 8,333,823 shares 140%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,259,576 USD 139%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $12,051,748 USD 671%
Deferred Tax Assets, Valuation Allowance $19,733,000 USD 9.2%
Deferred Tax Assets, Gross $19,864,000 USD 9.1%
Operating Lease, Liability $19,867 USD -79%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $7,763,068 USD -27%
Lessee, Operating Lease, Liability, to be Paid $20,019 USD -80%
Property, Plant and Equipment, Gross $52,548 USD 0%
Operating Lease, Liability, Current $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two $19,978 USD -0.1%
Lessee, Operating Lease, Liability, to be Paid, Year One $20,019 USD -75%
Operating Lease, Weighted Average Discount Rate, Percent 0.092 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $152 USD
Preferred Stock, Shares Issued 150 shares
Operating Lease, Payments $17,885 USD -11%
Additional Paid in Capital $15,124,219 USD 6.7%
Amortization of Intangible Assets $30,000 USD 0%
Depreciation, Depletion and Amortization $25,460 USD -41%
Deferred Tax Assets, Net of Valuation Allowance $131,000 USD 4%
Share-based Payment Arrangement, Expense $400,000 USD 400%